Current Status and Future Trends of Cold Atmospheric Plasma as an Oncotherapy
10.4062/biomolther.2023.027
- Author:
Xiaofeng DAI
1
;
Jiale WU
;
Lianghui LU
;
Yuyu CHEN
Author Information
1. The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China
- Publication Type:Review
- From:Biomolecules & Therapeutics
2023;31(5):496-514
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cold atmospheric plasma (CAP), a redox modulation tool, is capable of inhibiting a wide spectrum of cancers and has thus been proposed as an emerging onco-therapy. However, with incremental successes consecutively reported on the anticancer efficacy of CAP, no consensus has been made on the types of tumours sensitive to CAP due to the different intrinsic characteristics of the cells and the heterogeneous design of CAP devices and their parameter configurations. These factors have substantially hindered the clinical use of CAP as an oncotherapy. It is thus imperative to clarify the tumour types responsive to CAP, the experimental models available for CAP-associated investigations, CAP administration strategies and the mechanisms by which CAP exerts its anticancer effects with the aim of identifying important yet less studied areas to accelerate the process of translating CAP into clinical use and fostering the field of plasma oncology.
